Early Phase Development and Manufacture
Serious About Difficult Science from Day One
The success of a small molecule development programme is determined long before clinical manufacture begins.
Early-phase development is where complex chemistry, scalability risks, impurity challenges and regulatory expectations first emerge. Addressing these challenges early can accelerate timelines, reduce development risk and create a stronger pathway to clinical success.
Our integrated early-phase development teams combine process chemistry, analytical sciences, manufacturing and regulatory expertise to transform promising molecules into robust, scalable and clinically ready processes
Solving Challenges Before They Become Problems
Complex molecules rarely follow straightforward development pathways.
Our scientists work alongside clients to identify and resolve the critical technical challenges that could impact future drug substance scale-up, manufacturability, quality and supply. Beginning with the medicinal chemistry route, we evaluate process robustness, optimise yields, enhance impurity control and develop scalable manufacturing strategies designed for long-term success.
Through a science-led approach, we help clients make informed decisions earlier, reducing risk as programmes advance toward clinical manufacture.
Process Development Built for Scale
Developing a process is about more than producing material. It is about creating a commercially viable route that can withstand future regulatory, operational and manufacturing demands.
Our team applies extensive expertise in:
- Route scouting and optimisation
- Process development and scale-up
- Reaction understanding and control
- Impurity and purity management
- Thermal safety assessment
- Development of scalable purification strategies
- Quality by Design (QbD) principles
Supported by in-house calorimetry, DSC and safety assessment capabilities, we build processes that are designed for reliable clinical and commercial manufacture from the outset.
API Analytical Expertise That Drives Development Forward
Difficult science demands deeper analytical understanding.
Our analytical scientists work as an integrated extension of the development team, generating the data required to support confident decision-making throughout development. From reaction monitoring and impurity profiling to stability-indicating methods and genotoxic impurity assessment, we ensure every process is built on a strong analytical foundation.
With significant experience supporting complex small molecules, highly potent compounds, peptides and emerging modalities, we develop phase-appropriate analytical strategies that enable progression with confidence.
One Team. One Development Strategy.
Scientific continuity is one of the biggest advantages in early development.
By integrating chemistry, analytical development, manufacturing and regulatory expertise within a single organisation, Almac eliminates the challenges associated with multiple handovers and external transfers.
The result is:
- Faster development timelines
- Reduced technology transfer risk
- Greater project visibility
- Stronger process understanding
- More efficient progression to GMP manufacture
One team. One programme. One shared scientific objective.
From Discovery Route to Clinical Candidate
Whether your programme involves complex synthetic chemistry, challenging impurities, difficult scale-up requirements or aggressive timelines, our scientists provide the expertise needed to move confidently into clinical development.
Because difficult science should never become a barrier to progress.